Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Correction: Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Bibliographic Details
Main Authors:	Sophia Ceder, Sofi E. Eriksson, Ying Yu Liang, Emarndeena H. Cheteh, Si Min Zhang, Kenji M. Fujihara, Julie Bianchi, Vladimir J. N. Bykov, Lars Abrahmsen, Nicholas J. Clemons, Pär Nordlund, Sean G. Rudd, Klas G. Wiman
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-08-01
Series:	Cell Death and Disease
Online Access:	https://doi.org/10.1038/s41419-022-05130-y

Similar Items

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
by: Sophia Ceder, et al.
Published: (2021-07-01)

A thiol‐bound drug reservoir enhances APR‐246‐induced mutant p53 tumor cell death
by: Sophia Ceder, et al.
Published: (2021-02-01)

Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy
by: Vladimir J.N. Bykov, et al.
Published: (2016-02-01)

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246
by: Lena Haffo, et al.
Published: (2018-08-01)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
by: Luke Maese, et al.
Published: (2022-06-01)

LIPID PROFILES IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA ON L-ASPARAGINASE THERAPY
by: Janan G. Hasan
Published: (2010-12-01)

Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases
by: Judit Müller, et al.
Published: (2023-07-01)

Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia
by: Soulaimane M'harzi, et al.
Published: (2022-01-01)

PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
by: Camile Valle Medawar, et al.
Published: (2020-01-01)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
by: Wafa Chenbah, et al.
Published: (2023-08-01)

Corrigendum to Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia
by: Aziza Elouali, et al.
Published: (2023-01-01)

L-Asparaginase Toxicity in the Treatment of Children and Adolescents with Acute Lymphoblastic Leukemia
by: Madalina-Petronela Schmidt, et al.
Published: (2021-09-01)

Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients
by: Rytting ME
Published: (2012-06-01)

Allergic complications of L-asparaginase therapy in children with acute lymphoblastic leukaemia
by: Konstantinidis Georgios, et al.
Published: (2011-01-01)

l‑Asparaginase from Solanum lycopersicum as a Nutraceutical for Acute Lymphoblastic Leukemia
by: Sarina P. Khabade, et al.
Published: (2024-01-01)

Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia
by: Augusto F. Andrade, et al.
Published: (2014-08-01)

Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy
by: Juluri KR, et al.
Published: (2022-05-01)

Coagulation abnormality as a complication of L-asparaginase therapy in childhood lymphoblastic leukemia
by: Djajadiman Gatot, et al.
Published: (2016-10-01)

Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia
by: Soumika Sengupta, et al.
Published: (2024-05-01)

Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach
by: Adesh Baral, et al.
Published: (2021-09-01)

Toxicity profile of L-asparaginase in children with acute lymphoblastic leukaemia – Single centre experience
by: Rachel Priyanka Pulla, et al.
Published: (2016-01-01)

The Outcome of Children With Acute Lymphoblastic Leukemia Without Receiving Sufficient Dose of L-Asparaginase
by: Gholamreza Bahoush, et al.
Published: (2020-07-01)

Concurrent diabetic ketoacidosis and pancreatitis in Paediatric acute lymphoblastic leukemia receiving L-asparaginase
by: Patel Zeeshan Jameel, et al.
Published: (2020-05-01)

Asparaginase Therapy in Pediatric Acute Lymphoblastic Leukemia: A Focus on the Mode of Drug Resistance
by: Shih-Hsiang Chen
Published: (2015-10-01)

Hypoglycemia associated with L-asparaginase in acute lymphoblastic leukemia treatment: a case report
by: Tanaka Ryuma, et al.
Published: (2012-04-01)

Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN
by: Angelos Heldin, et al.
Published: (2023-12-01)

Monitoring asparaginase activity to improve the management of patients with acute lymphoblastic leukemia: Experience in one center
by: Marina García Morin, et al.
Published: (2024-01-01)

Associations of T-Cell Receptor Repertoire Diversity with L-Asparaginase Allergy in Childhood Acute Lymphoblastic Leukemia
by: Shawn H. R. Lee, et al.
Published: (2023-03-01)

Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity.
by: Nóra Kutszegi, et al.
Published: (2015-01-01)

Coagulation abnormalities in childhood acute lymphoblastic leukemia: assessing the impact of L-asparaginase therapy in Ghana
by: William Osei-OWusu, et al.
Published: (2021-06-01)

Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia
by: Delphine Verbeke, et al.
Published: (2019-12-01)

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
by: Michael Müller, et al.
Published: (2021-09-01)

Peer Review of “Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach“
by: Ariz Mohammad
Published: (2021-09-01)

P331: T-CELL RECEPTOR REPERTOIRE DIVERSITY AND L-ASPARAGINASE HYPERSENSITIVITY IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
by: S. Lee, et al.
Published: (2022-06-01)

Peer Review of “Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach“
by: Navneetha Hardikar
Published: (2021-09-01)

Peer Review of “Selection of the Optimal L-asparaginase II Against Acute Lymphoblastic Leukemia: An In Silico Approach”
Published: (2021-09-01)

Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment
by: Cristina Díaz-Barriga, et al.
Published: (2021-04-01)

Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line
by: Iris Munhoz Costa, et al.
Published: (2023-07-01)

Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia
by: Tong Lin, et al.
Published: (2023-05-01)

A study of the adverse drug reactions of L-asparaginase in newly diagnosed children with acute lymphoblastic leukemia
by: Harshada Uchil, et al.
Published: (2017-01-01)